132 related articles for article (PubMed ID: 2391704)
1. NMR studies of configuration and tautomeric equilibria in nitroacridine antitumor agents.
Boyd M; Denny WA
J Med Chem; 1990 Sep; 33(9):2656-9. PubMed ID: 2391704
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-selective antitumor agents. 4. Relationships between structure, physicochemical properties, and hypoxia-selective cytotoxicity for nitracrine analogues with varying side chains: the "iminoacridan hypothesis".
Denny WA; Atwell GJ; Anderson RF; Wilson WR
J Med Chem; 1990 May; 33(5):1288-95. PubMed ID: 2329552
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine.
Wilson WR; Anderson RF; Denny WA
J Med Chem; 1989 Jan; 32(1):23-30. PubMed ID: 2909736
[TBL] [Abstract][Full Text] [Related]
4. Intercalation model for DNA-cross linking in a 1-nitro-9-aminoacridine derivative, an analog of the antitumor agent "ledakrin" (nitracrine).
Stallings WC; Glusker JP; Carrell HL; Bogucka-Ledóchowska M; Ledóchowski A; Stezowski JJ
J Biomol Struct Dyn; 1984 Dec; 2(3):511-24. PubMed ID: 6400911
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
[TBL] [Abstract][Full Text] [Related]
6. 32P-post-labeling analysis of DNA adduct formation by antitumor drug nitracrine (Ledakrin) and other nitroacridines in different biological systems.
Bartoszek A; Konopa J
Biochem Pharmacol; 1989 Apr; 38(8):1301-12. PubMed ID: 2706021
[TBL] [Abstract][Full Text] [Related]
7. 1H and 13C NMR characteristics of the anticancerous derivative of acridine: Ledakrin C-283 (nitracrine).
Wieczorkiewicz T; Lubas B; Siatecki Z; Kozłowski H
Acta Biochim Pol; 1983; 30(1):71-82. PubMed ID: 6868905
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of 1-nitro-9-aminoacridines including nitracrine against some ascitic experimental tumors.
Mazerska Z; Lukowicz J; Konopa J
Arzneimittelforschung; 1990 Apr; 40(4):472-7. PubMed ID: 2357249
[TBL] [Abstract][Full Text] [Related]
9. Frameshift mutations induced by four isomeric nitroacridines and their des-nitro counterpart in the lacZ reversion assay in Escherichia coli.
Hoffmann GR; Yin CC; Terry CE; Ferguson LR; Denny WA
Environ Mol Mutagen; 2006 Mar; 47(2):82-94. PubMed ID: 16180206
[TBL] [Abstract][Full Text] [Related]
10. Anaerobic incubation and mutagenicity of nitracrine analogues in Salmonella typhimurium.
Ferguson LR; Roberton AM; Turner PM
Mutagenesis; 1987 Jul; 2(4):253-7. PubMed ID: 3325754
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of 1-nitro-9-aminoacridine derivatives.
Hrabowska M; Mazerska Z; Lukowicz JP; Onoszko K; Ledóchowski A
Arzneimittelforschung; 1982; 32(9):1013-6. PubMed ID: 6890816
[TBL] [Abstract][Full Text] [Related]
12. DNA damage in HeLa s3 cells by an antitumor drug Ledakrin and other antitumor 1-nitro-9-aminoacridines.
Woynarowski JM; Bartoszek A; Konopa J
Chem Biol Interact; 1984 May; 49(3):311-28. PubMed ID: 6722943
[TBL] [Abstract][Full Text] [Related]
13. QSAR of acridines. II. Features of nitracrine analogs for high anti-tumor activity and selectivity on mice, searched by PCA and MRA methods.
Mazerska Z; Mazerski J; Ledóchowski A
Anticancer Drug Des; 1990 May; 5(2):169-87. PubMed ID: 2357263
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
Wilson WR; Thompson LH; Anderson RF; Denny WA
J Med Chem; 1989 Jan; 32(1):31-8. PubMed ID: 2909741
[TBL] [Abstract][Full Text] [Related]
15. A search for antitumor compounds. XI. Biologic studies. Antitumor properties of 19 new 9-aminoacridine and 1-or 3-nitro-9-aminoacridine derivatives.
Hrabowska M; Ledóchowski A; Onoszko K
Arch Immunol Ther Exp (Warsz); 1976; 24(2):249-58. PubMed ID: 1275662
[TBL] [Abstract][Full Text] [Related]
16. Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells.
Wiśniewska A; Niemira M; Jagiełło K; Potęga A; Swist M; Henderson C; Skwarska A; Augustin E; Konopa J; Mazerska Z
Biochem Pharmacol; 2012 Jul; 84(1):30-42. PubMed ID: 22484277
[TBL] [Abstract][Full Text] [Related]
17. Potential antitumor agents. 49. 5-substituted derivatives of N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide with in vivo solid-tumor activity.
Denny WA; Atwell GJ; Rewcastle GW; Baguley BC
J Med Chem; 1987 Apr; 30(4):658-63. PubMed ID: 3560160
[TBL] [Abstract][Full Text] [Related]
18. Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide.
Rewcastle GW; Atwell GJ; Chambers D; Baguley BC; Denny WA
J Med Chem; 1986 Apr; 29(4):472-7. PubMed ID: 3959026
[TBL] [Abstract][Full Text] [Related]
19. Frameshift mutagenesis by nitracrine analogues in wild-type, uvrB, polA and recA strains of Salmonella typhimurium, with and without plasmid pKM101.
Ferguson LR; Turner PM
Mutat Res; 1987 Jul; 184(1):13-21. PubMed ID: 3037366
[TBL] [Abstract][Full Text] [Related]
20. Induction of DNA-protein crosslinks by antitumor 1-nitro-9-aminoacridines in L1210 leukemia cells.
Woynarowski JM; McNamee H; Szmigiero L; Beerman TA; Konopa J
Biochem Pharmacol; 1989 Nov; 38(22):4095-101. PubMed ID: 2557039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
